PYC Therapeutics Limited
PYCXF
$0.8462
$0.178626.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 32.88% | 35.98% | 5.19% | 2.60% | 154.20% |
| Total Revenue | 32.88% | 35.98% | 5.19% | 2.60% | 154.20% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 32.88% | 35.98% | 5.19% | 2.60% | 154.20% |
| SG&A Expenses | 12.96% | 15.60% | 22.44% | 19.41% | 0.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.26% | 61.96% | 91.71% | 86.98% | 18.15% |
| Operating Income | -72.92% | -76.96% | -256.22% | -247.43% | 9.73% |
| Income Before Tax | -69.52% | -73.48% | -251.44% | -242.76% | 10.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.52% | -73.48% | -251.44% | -242.76% | 10.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 81.40% | 85.82% | 263.19% | 259.22% | -77.19% |
| Net Income | -69.39% | -73.35% | -240.83% | -232.41% | 7.89% |
| EBIT | -72.92% | -76.96% | -256.22% | -247.43% | 9.73% |
| EBITDA | -74.82% | -78.90% | -259.63% | -250.75% | 9.25% |
| EPS Basic | -37.69% | -40.46% | -167.65% | -163.77% | 22.62% |
| Normalized Basic EPS | -37.04% | -40.74% | -162.79% | -156.82% | 20.59% |
| EPS Diluted | -37.69% | -40.46% | -167.65% | -163.77% | 22.62% |
| Normalized Diluted EPS | -37.04% | -40.74% | -162.79% | -156.82% | 20.59% |
| Average Basic Shares Outstanding | 23.66% | 23.66% | 26.60% | 26.60% | 18.52% |
| Average Diluted Shares Outstanding | 23.66% | 23.66% | 26.60% | 26.60% | 18.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |